On November 15, 2020, Acacia Research Corporation ("Acacia") announced that it has completed the monetization of its Woodford Life Science portfolio.  The company announced today that it has agreed to pay over $1 billion to acquire Oxford Nanopore Technologies, a microcap company.  According to the company's press release announcing the acquisition, Acacia's cash and equity investments totaled $605 million in the third quarter of 2020.  According to the company's press release, Acacia sold approximately 10% of its position in the Oxford Nanopore Technologies portfolio, generating net proceeds of approximately $22 million in the quarter.  The company also announced that it has entered into a six-month lockup for its remaining shares.  According to the SEC's press release, Acacia's book value was about $1 billion and it booked $100 million in realized and unrealized gains for the quarter.  The company's revenue was $19.5 million in the quarter.  The company's operating loss was $12.7 million in the quarter.  The company's net income was $104.2 million in the quarter.  The company's stock price rose significantly, and Acacia's book value increased by $33 million.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, charges Acacia with violations of the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  The complaint seeks permanent injunctions, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties.  The SEC's investigation, which is continuing, is being conducted by Janney Montgomery Scott and Kelly Loomis of the SEC's Market Abuse Unit.  The litigation will be led by Mr. Scott and Ms. Montgomery Scott.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.